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Objective: Our goal was to determine the role of pulmonary endothelial
nitric oxide synthase expression in the development of pulmonary hyper-
tension in infants with congenital cyanotic heart disease. Methods: Two
groups of 4-week-old piglets were studied. In one group, the piglets were
raised in an environment of 10% oxygen from 2 days of age (cyanotic, n 5
6), and in the other group the piglets were raised at room air (control, n 5
5). Pulmonary hemodynamics were measured in vivo for each animal, and
peripheral lung biopsy specimens were obtained for Western blot analysis
with the use of antiendothelial nitric oxide synthase antibody and for
activity analysis with the use of the tritiated L-arginine assay. Results: The
piglets in the chronically hypoxic group had significant increases in mean
pulmonary arterial pressure (44.0 6 3.8 mm Hg vs 14.8 6 1.2 mm Hg in
controls, p 5 0.0007) and pulmonary vascular resistance (7272.0 6 871.1
dyne z cm z sec
–5 vs 1844.5 6 271.2 dyne z cm z sec–5 in controls, p 5 0.002).
These changes in the pulmonary hemodynamics of the hypoxic piglets were
accompanied by a twofold increase in the expression of pulmonary endo-
thelial nitric oxide synthase (p 5 0.0043) but no corresponding increase in
nitric oxide synthase activity. Conclusions: Raising infant piglets in an
environment of 10% oxygen for 4 weeks results in significant pulmonary
arterial hypertension accompanied by increased expression of nitric oxide
synthase within the lung endothelium. Furthermore, the increased levels of
nitric oxide synthase within the lungs of the hypoxic swine were not
accompanied by a proportional increase in enzyme activity. These findings
suggest that the development of pulmonary hypertension in infants with
congenital cyanotic disease is not due to decreased expression of endothe-
lial nitric oxide synthase, but instead may be related to a decreased ability
of the enzyme to produce sufficient nitric oxide. (J Thorac Cardiovasc Surg
1998;115:343-50)
Pulmonary hypertension is a common and seriousmanifestation of congenital cyanotic heart dis-
ease, yet its underlying pathophysiologic mechanism
has not been fully elucidated. Historically, investi-
gators have focused on the roles of increased pul-
monary arterial flow or obstructed pulmonary ve-
nous flow and the development of arterial smooth
muscle hypertrophy characterizing the hypertensive
state. The molecular mechanisms underlying these
physiologic events, however, were largely unpursued
until the identification of nitric oxide (NO) as the
endothelium-derived vascular smooth muscle relax-
ant described by Furchgott and Zawadski1 in
1980.2, 3
NO is produced within endothelial cells by the
enzyme endothelial nitric oxide synthase (eNOS).4
The reaction catalyzed by eNOS is dependent on the
intracellular presence of calcium and calmodulin
and also requires the presence of certain cofactors
including tetrahydrobiopterin and reduced nicotin-
amide adenine dinucleotide phosphate (NADPH).5
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The NO thus produced diffuses to nearby vascular
smooth muscle cells, where it causes a G-protein–
mediated increase in cyclic guanosine monophos-
phate, which in turn leads to smooth muscle cell
relaxation and thus vasodilatation.6 Because of its
role as a potent vasodilator and subsequent findings
that inhibition of its production enhances the devel-
opment of hypoxia-induced pulmonary vasoconstric-
tion, a deficiency in the production of NO has been
hypothesized to play a role in the development of
pulmonary hypertension in the setting of chronic
hypoxia.7-9
Whether this decrease in NO production is due to
decreased expression of eNOS has been studied in
both human beings and rats, but the results of these
investigations have been generally inconclusive.l0-13
Furthermore, most of these studies have involved
adult models. Our laboratory is specifically inter-
ested in the relationship between eNOS expression
and pulmonary hypertension as it applies to infants
with congenital cyanotic heart disease. Our aim in
this study was to develop a large-animal infant
model of hypoxia-induced pulmonary hypertension
and to determine the levels of pulmonary eNOS
protein and activity within this model. We hypothe-
sized that hypoxia-induced pulmonary hypertension
in infants is due to a decrease in the production of
NO, either through a reduction in the expression of
pulmonary eNOS or through a decrease in this
enzyme’s activity.
Materials and methods
Study groups. Eleven 4-week old De Kelb piglets (Wal-
nut Hill Farm, Hillsborough, N.C.) were studied. Six of
these piglets were raised from 2 days of age at an inspired
oxygen percentage of 10% (hypoxic group). The remain-
ing piglets were raised in 21% oxygen (control group).
Study group assignments were made in a randomized
fashion. Piglets in the hypoxic group were placed at 2 days
of age in a stainless-steel chamber and maintained in an
atmosphere of 10% oxygen and 90% nitrogen, with air
flow through the chamber being maintained at 16 L/min.
The oxygen content within the chamber was monitored at
all times (Beckman E.C, Oxygen Analyzer, Beckman
Instruments, Inc., Fullerton, Calif.). Soda lime was placed
in the chamber to prevent deleterious carbon dioxide
accumulation. These animals were exposed to room air
conditions for a mean of 20 minutes during each 24-hour
period for replenishment of food supply and maintenance
of the chamber. All animals received humane care in
compliance with the “Guide for the Care and Use of
Laboratory Animals” published by the National Institutes
of Health (NIH publication 85-23, revised 1985) and were
housed in the institution’s National Institutes of Health–
approved animal facility.
Data acquisition. At 4 weeks of age, anesthesia was
induced in each animal with an intramuscular injection of
ketamine (50 mg/kg) and acepromazine (15 mg/kg). Intra-
venous methylprednisolone (30 mg/kg) was administered
via an 18-gauge cannula in the marginal vein of the pinna.
Orotracheal intubation was performed and mechanical
ventilation (Infant Ventilator; Sechrist Industries, Ana-
heim, Calif.) was commenced to achieve an arterial oxy-
gen tension of 150 to 250 mm Hg and an arterial carbon
dioxide tension of 35 to 45 mm Hg. The animals were
paralyzed with intravenous pancuronium (300 mg/kg) and
anesthetized with fentanyl (100 mg/kg). Thereafter, anes-
thesia was maintained with a continuous infusion of
fentanyl (25 mg/kg per hour). An 18-gauge cannula was
placed in the left femoral artery for blood pressure
monitoring and arterial blood sampling. The heart was
exposed through a median sternotomy. Cardiac instru-
mentation consisted of micromanometers (Millar Instru-
ments, Inc., Houston, Tex.) inserted into the left atrium
and the main pulmonary artery and a 10 mm ultrasonic
flow probe (Transonic Systems, Ithaca, N.Y.) around the
proximal pulmonary artery.
eNOS protein analysis. A peripheral pulmonary biopsy
specimen was obtained from each animal and snap frozen
in liquid nitrogen after storage at –80° C. A portion of the
tissue from each hypoxic and control animal was later
thawed, weighed, and homogenized in 150 ml ice cold
tromethamine (Tris, 50 mmol/L) containing phenyl-
methyl-sulfonylfluoride (0.2 mg/ml), leupeptin (0.5 mg/
ml), and 0.1% octyphenoxy polyethoxyethanol (Triton
X-100, Union Carbide Corp., Canbury, Conn.). The ho-
mogenate was then lysed by sonication (Brinkman Instru-
ments, Inc., Westbury, N.Y.), and pelleted by centrifuga-
tion (Brinkman Instruments). Total protein concentration
of the supernatant was then determined by the Bradford
assay (Bio-Rad Laboratories, Richmond, Calif.) with bo-
vine serum albumin as the standard.14
Equal samples of protein were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis on 9%
polyacrylamide gels and then electrophoretically trans-
ferred to nitrocellulose membranes for Western blot
analysis. The membrane was then blocked in 7.5% nonfat
milk in tromethamine-buffered saline solution/polysor-
bate (Tween) and then incubated with primary monoclo-
nal anti-eNOS antibody at the manufacturer’s specified
concentration (Transduction Laboratories, Lexington,
Ky.) for 1 hour at room temperature. eNOS protein bands
were then visualized with antimouse immunoglobulin G
horseradish peroxidase-conjugated antibody followed by
chemiluminescence (DuPont, Boston, Mass.). The rela-
tive quantities of eNOS within the visualized protein
bands were then quantified by laser densitometry (LKB
Ultroscan XL, LKB Instruments, Inc., Rockville, Md.).
Relative protein quantity was expressed as the percentage
abundance in the control animals.
NOS activity. So that NOS activity in the lung tissue
could be determined, samples from each biopsy were lysed
by sonication in ice-cold, freshly prepared assay buffer
containing tromethamine (Tris, 20 mmol/L), pH 7.4,
ethylenediaminetetraacetic acid (EDTA, 1 mmol/L), and
protease inhibitors soy trypsin inhibitor (100 mg/ml),
Na-p-tosyl-L-lysine chloro-methyl keatone (TLCK, 50 mg/
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ml), phenylmethylsulfonyl fluoride (200 mg/ml), leupeptin
(0.5 mg/ml), pepstatin (0.7 mg/ml), aprotinin (1 mg/ml),
and antipain (50 mg/ml). So that NOS activity would be
preserved, the buffer also contained NOS cofactors flavin
adenine dinucleotide (5 mmol/L), flavin mononucleotide
(5 mmol/L), biopterin (7 mmol/L), and diphtheria tetanus
toxoid (DTT, l mmol/L). The cellular debris were then
pelleted by centrifugation and 10 ml of the remaining
lysate was added to 100 ml of a pre-prepared assay buffer
mix containing calmodulin (150 nmol/L), calcium dichlo-
ride (1.75 mmol/L), biopterin (7.3 mmol/L)/DTT (1.33
mmol/L), 3[H]-arginine (1 mCi; 2 3 106 dpm [disintegra-
tions per minute]), and NADPH (1 mmol/L), which was
added last. The assay buffer and lysate sample were
incubated at 30° C for 10 minutes, and the reaction was
then stopped with the addition of 2 ml of stop solution
(HEPES, 20 mmol/L; pH 5.5; EDTA, 2 mmol/L). The
reaction wells were then washed with 2 ml of stop solution
and the total mixture was then poured over a 1 ml silver
50W-X8 (sodium form) resin column (Bio-Rad 143-1451,
Bio-Rad Laboratories), which had been pre-washed with 2
ml of stop solution. The flow through was collected and
then the column was washed with an additional 2 ml of
stop solution. Eluate (500 ml) was placed in scintillation
vials quantified by liquid scintillation spectroscopy. The
sample used for background calculation was processed in
exactly the same manner, whereas the sample used for
total counts was added directly to stop solution without
column purification. The proportion of arginine that was
convened to citrulline (and therefore the production of
NO) was calculated as follows: (Disintegrations per
minute in sample – Background disintegrations per
minute)/(Total disintegrations per minute). To convert
this proportion to moles of NO, we calculated the total
quantity of arginine in the assay from the total disintegra-
tions per minute (with a factor of 8 since only 500 ml was
counted) and the known specific activity of 3[H]-arginine.
NOS activity was then expressed as picomoles NO pro-
duced per milligrams of tissue per minute of incubation.
Statistical analysis. The pulmonary hemodynamic vari-
ables, eNOS protein levels, and NOS activity between the
control and hypoxic groups were compared by nonpaired
Student’s t tests. All results are expressed as mean 6
standard error of the mean. eNOS protein levels are
expressed as a percentage of abundance in normoxic
control lung.
Results
Study groups. Eleven 4-week-old piglets were
studied, with six being raised from 2 days of age at
an inspired oxygen fraction of 10% (hypoxic group,
n 5 6) and the remainder being raised breathing
room air (control group, n 5 5). At the time of in
vivo data acquisition, all pigs were mechanically
ventilated at a normoxic inspired oxygen fraction.
No discernible difference was observed between the
two groups with regard to mean weight (6.52 6 0.89
kg for hypoxic group vs 7.80 6 0.19 kg for control
group, p 5 0.232), mean heart rate (117.9 6 8.0
beats/min for hypoxic group vs 127.3 6 6.7 beats/
min for control group, p 5 0.392), or mean arterial
pressure (73.6 6 11.6 mm Hg for hypoxic group vs
68.6 6 2.0 mm Hg for control group, p 5 0.693). The
cardiac index was also similar for the two groups,
averaging 80.2 6 5.4 ml z min–1 z kg–1 in the hypoxic
piglets and 91.3 6 14.3 ml z min-1 z kg-1 in the control
piglets (p 5 0.499). Although the mean hematocrit
value of the hypoxic animals was significantly
greater that of the control animals (39% 6 2% in
the hypoxic group vs 27% 6 1% in the control
group, p 5 0.003), no difference was detected in the
oxygen saturations of the two groups while they
were breathing room air (0.999 6 0.006 in the
hypoxic group vs 0.999 6 0.002 in the control group,
p 5 0.207).
Pulmonary hemodynamics and ventricular
weights. While undergoing mechanical ventilation
at normoxic conditions, the hypoxic animals had
significant increases in both mean pulmonary vascu-
lar pressure and pulmonary vascular resistance
when compared with the control animals (Table I).
The right ventricular masses were significantly
greater in the hypoxic animals than in the control
animals, but the left ventricular masses did not
differ. This resulted in a threefold increase in the
right ventricle/left ventricle weight ratio in the hy-
poxic animals (Table I).
Pulmonary eNOS analysis. When the 153 kd
eNOS bands obtained from Western blot analysis
(Fig. 1) were quantified by laser densitometry, we
found that the pulmonary eNOS levels were in-
creased 2.01-fold in the hypoxic animals when com-
pared with the control animals (Fig. 2). Despite the
Table I. Pulmonary hemodynamic variables
and ventricular weights for the hypoxic and control
groups
Variable
Hypoxic
(n 5 6)
Control
(n 5 5) p Value
PVR (dynezcmzsec25) 7272.0 (871.1) 1844.5 (271.2) 0.002
MPAP (mmHg) 44.0 (3.8) 14.8 (1.2) 0.0007
RV mass (gm) 20.4 (2.7) 7.3 (0.2) 0.008
LV mass (gm) 20.1 (1.9) 22.4 (1.3) 0.344
RV/LV mass ratio 1.00 (0.05) 0.33 (0.01) 0.0002
Pulmonary hemodynamic data were measured in vivo during normoxic
mechanical ventilation. The increases in mean pulmonary arterial pressure
and pulmonary vascular resistance in the hypoxic animals indicate the
development of substantial pulmonary arterial hypertension. Postmortem
examinaiton of ventricular mass indicates a hypertrophic right ventricular
response to the increased pulmonary pressures in the hypoxic piglets. All
values are expressed as mean 6 standard error of the mean. PVR,
Pulmonary vascular resistance; MPAP, mean pulmonary arterial pressure;
RV, right ventricular; LV, left ventricular.
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increased levels of eNOS in the lungs of the hypoxic
animals, the total NOS activity per milligram of lung
protein did not differ between the two groups (Fig.
3).
Discussion
In this study, we show that raising newborn piglets
in an environment of 10% oxygen for 4 weeks results
in pulmonary arterial hypertension as evidenced by
significant increases in main pulmonary arterial
pressure and pulmonary vascular resistance in com-
parison with age-matched piglets raised in room air.
A consequence of this pulmonary arterial hyperten-
sion was the development of right ventricular hyper-
trophy, a finding that further validates our model of
chronic neonatal hypoxia. These changes in the
pulmonary hemodynamics of the hypoxic piglets
took place without a significant alteration in cardiac
index, suggesting that hypoxia alone can produce
pulmonary hypertension without the presence of
increased flow through the pulmonary vessels.
Western blot analysis on lung biopsy tissue from
all study animals using specific anti-eNOS antibody
revealed that the hypoxic piglets had twofold more
pulmonary eNOS than the control piglets, suggest-
ing that neonatal pulmonary eNOS expression is
up-regulated in the setting of chronic hypoxia. We
then performed in vitro assays on the lung samples
for the conversion of 3[H]-arginine to 3[H]-citrulline
to determine the activity of the NOS present within
the lungs. The assay was performed in room air with
an excess of L-arginine and all the cofactors used by
the enzyme. We found no significant difference in
the activity of NOS per milligram of lung protein
between the hypoxic and control groups. Inasmuch
as the enzyme concentration was 101% higher in the
hypoxic animals, a corresponding increase in the
activity of NOS per milligram of lung protein would
be expected. The absence of such a proportional
increase suggests that the intrinsic ability of the
enzyme to produce NO is impaired in the hypoxic
animals. One possible explanation for this decrease
in NOS activity is that the hypoxic piglets had
reduced levels of molecular oxygen, a crucial sub-
strate in the production of NO by the synthase
enzyme.15 Similarly, a reduction in the availability of
L-arginine, the other substrate in the NOS reaction,
may also account for the decreased production of
NO.16 However, such deficiencies do not explain the
in vitro reduction in NOS activity that we demon-
strate because this assay was performed in room air
with an excess of L-arginine. This indicates that the
eNOS enzyme itself may be functionally impaired in
chronic hypoxia.
Our finding of increased pulmonary expression of
eNOS production in the chronically hypoxic infant
swine contrasts with results from anoxic cultured
human vascular endothelial cells17 and in adult
patients with pulmonary hypertension of various
causes,13 both of which have shown a reduction in
the expression of eNOS messenger ribonucleic acid.
These results would suggest that chronic hypoxia
compromises the ability of pulmonary vascular en-
dothelium to produce NOS. However, studies in
adult rats support our findings of overexpression of
pulmonary eNOS in chronic hypoxia. For example,
exposing adult rats to hypoxia for extended period
of time has repeatedly been shown to result in
increased levels of both eNOS messenger ribonu-
cleic acid and protein.l0-12 Other investigations have
shown that the pulmonary hypertension in adult rats
can be significantly reduced if the rats are exposed
to low levels of inhaled NO during hypoxia, indicat-
ing that the production of NO is deficient despite an
overexpression of the enzyme that produces it.18
Although neonatal piglets are clearly different from
human infants, swine were chosen in this model
because of their anatomic and physiologic similari-
ties to human beings.
Although our model shares many of the advan-
tages of the adult rodent model, especially the
ability to expose the experimental subjects to low
oxygen levels in a standardized laboratory setting, an
important difference is that our model attempts to
Fig. 1. Laser scan of Western blot showing the 153 kd eNOS bands in the control and hypoxic animals.
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explain the relationship between hypoxia-induced
pulmonary hypertension and eNOS expression in an
infant model. Because the endothelium-dependent
vasodilatory capabilities of pulmonary vessels are
likely to show maturational variations,19, 20 it is
important to use an infant model when examining
the relationship between eNOS and pulmonary hy-
pertension caused by congenital cyanotic heart dis-
ease. Recent investigations of isolated lungs from
chronically hypoxic neonatal swine have shown a
dampened response of these lungs to the endothe-
lium-dependent vasodilatory agent acetylcholine
when compared with age-matched normoxic control
animals.21 When exposed to N-nitro-L-arginine
methyl ester (L-NAME), a known inhibitor of
NOS,22 the lungs from the control animals showed
Fig. 2. Quantitative densitometry of the protein bands obtained from Western blot analysis revealed a
twofold increase in eNOS levels in the lungs of the hypoxic piglets. Protein levels are expressed as
percentage of abundance in the control animals. Statistical analysis was performed by means of the
Student’s t test.
Fig. 3. NOS activity was determined by means of the 3[H]-arginine conversion assay, with the results being
expressed as rate of activity per milligram of total lung protein. There was no detectable difference in the
total NOS activity between the two groups.
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significant vasoconstriction whereas the hypoxic
lungs showed no response. These results suggest
that the production of NO in the lungs of the
hypoxic swine is reduced, thus supporting our find-
ing of decreased eNOS activity in chronically hy-
poxic newborn piglets.
Importantly, our study addresses the effects of
chronic hypoxia on the expression of pulmonary
eNOS in newborn infants. We demonstrate that the
development of hypoxia-induced pulmonary hyper-
tension in neonates is associated with an overexpres-
sion of pulmonary eNOS, indicating that the ability
of the pulmonary vascular endothelium to support
the production of this enzyme is not limited by
chronic hypoxia, and may in fact be stimulated by
chronic hypoxia. Furthermore, we have shown that
the ability of this enzyme to produce NO may be
reduced in the setting of chronic hypoxia and that
this decrease in enzyme function may contribute to
the development of pulmonary hypertension. There-
fore, efforts in treating infants with pulmonary hy-
pertension associated with cyanotic heart disease
should be directed toward understanding the mech-
anisms of decreased eNOS activity and increasing
the production of NO.
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Discussion
Dr. Frank L. Hanley (San Francisco, Calif.). It appears
that you have created a nice neonatal large-animal model
of chronic hypoxic pulmonary hypertension. It also seems
clear that in this model, eNOS is elevated in the hypoxic
animals. Beyond that is a great deal of room for specula-
tion and discussion. This is a very interesting area for
research with much potential clinical application. I en-
courage you and your group to continue to work in this
area.
I have three separate areas for further discussion. The
first relates to interpretation of your data. You have
shown that eNOS doubles, but interestingly, when you
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take the enzyme and challenge it in vitro to determine
how much NO it actually makes, it does not appear to
make any more than the samples from the control popu-
lation. Have you evaluated this any further? Is the actual
enzyme itself altered or is an associated inhibitor in your
lysate competing with the enzyme. Along those lines, are
you implying any kind of cause and effect with the
pulmonary hypertension? Pulmonary vascular tone has
multiple regulators. Is it possible that your elevated eNOS
is simply a marker of other mechanisms and this elevation
is simply a reaction to increased vasoactive tone caused by
multiple other factors?
Mr. Scarborough. Those are very good points. The
activity assay that we used has a couple of limitations that
should be noted. First, it is an in vitro assay, which takes
the process of NO production away from the body and the
in vivo circumstances. Second, the assay is not specific for
the endothelial isoform, so we cannot say that eNOS per
se is not significantly increased. However, we do not think
a reduction in another isoform’s activity is masking an
increase in the enzyme’s activity. We are currently doing
some follow-up studies to investigate why the activity of
NOS may be decreased. A couple of possibilities that have
been suggested in prior literature are possible deficiencies
in the substrates L-arginine and molecular oxygen. Be-
cause our in vitro assay was performed with an excess of
these substrates, we believe that deficiencies in these
substrates are not a likely cause. Other explanations
include the cofactors; one of particular interest is tetrahy-
drobiopterin. Although we have not examined this rela-
tionship further, some of the literature on coronary ath-
erosclerosis has speculated that a deficiency in
tetrahydrobiopterin may reduce the enzyme’s activity and
that these reductions may not be correctable merely by
adding the cofactor in its preformed form into an in vitro
assay. We would like to investigate that further. Also, we
have undertaken a similar study in 2-week-old hypoxic
piglets in which the vasodilatory response to acetylcholine
in 2-week-old hypoxic animals was much less than in
2-week-old control animals, an observation that does
seem to back up our findings in the in vitro assay that we
used for the 4-week-old animals. It is, however, possible
that there is an enzyme in the lysate that somehow
interferes with the enzyme’s ability to produce NO.
Dr. Hanley. The second point for discussion relates to
methods. You have shown that the enzyme is doubled in
the hypoxic tissue from your biopsy. Have you considered
the following potential problem? These are neonatal
piglets that have hyperplastic potential in their lung tissue
and lung vascular tissue. Have you done any morphomet-
ric studies or assays of other endothelial protein to rule
out the possibility that you are stimulating more vascula-
ture here, and therefore, when you get 1 gm of lung tissue,
you may actually have twice as much vessel and twice as
much endothelium so when you look at the samples, you
find you have twice as much eNOS but not twice as much
expression?
The third point relates more to the appropriateness of
the model. You emphasized that you were trying to mimic
cyanotic congenital heart disease with this model. I would
argue that you have created a very nice model for
mountain sickness, but breathing thin air is not a model of
cyanotic congenital heart disease. These animals are
breathing lower oxygen concentrations, but they have no
intracardiac mixing and they have absolutely normal pul-
monary blood flow. What their vascular endothelium is
seeing in your model is very different from that in the
example of cyanotic congenital heart disease clinically.
Cyanotic animals are hypoxemic because of mixing and
sometimes reduced pulmonary blood flow, but the blood
that does go through the microvasculature of the lung is
no different than in you or me. A normal individual
breathes in room air and oxygenates it; a cyanotic individ-
ual does the same thing. Your model is very different. This
is still a very important study, but to say that it is an
example of what happens in cyanotic congenital heart may
well not be correct. I would like your input on this
observation.
Mr. Scarborough. The alternative to our method of
producing pulmonary hypertension would be to try to
construct a shunt in a newborn piglet; we avoided that
because we thought it might introduce too many other
variables of injury that would cloud the issue. In develop-
ing our model, we used as our primary basis the work of
another Duke group headed by Dr. James Lowe, who had
constructed this hypoxic model to look at myocardial con-
tractility in chronic hypoxia. Our method of producing
chronic hypoxia is consistent with those of other investigators
studying the effects of hypoxia on eNOS production.
Dr. Hanley. I think you are doing an excellent job in a
complex area that has great potential for clinical applica-
tion, and I would encourage you to continue this work.
Dr. David A. Fullerton (Winnetka, Ill.). I would like to
echo some of the comments made earlier. The model you
have used is a standard model to develop pulmonary
hypertension. Work published in the early 1990s nicely
demonstrated in sheep that throughout the newborn
period for approximately 2 weeks after birth the amount
of eNOS is diminished. It is part of the maturation
problem, and it is thought that this may contribute to
higher pulmonary arterial pressures in newborn infants.
Work has shown that through augmented expression of
vascular endothelial growth factor, there is a proliferation
of capillaries including endothelial cells. Do you have any
histologic studies looking at neovascularization as part of
your explanation for some of your findings?
Mr. Scarborough. We do have specimens for histologic
studies. However, we have not looked at those and we
have not done morphometric analysis at this time.
Dr. Fullerton. It is paradoxical that you find elevated
levels of eNOS in the presence of very high pulmonary
arterial pressure. I realize that is the whole crux of your
issue. It turns out that there is a strain of rats that
spontaneously become pulmonary hypertensive, and they
too share this paradox; they have high levels of eNOS, yet
very high pulmonary arterial pressures. Could you specu-
late on how this happens? Is it possible that the eNOS is
a compensatory response to the hypoxia-induced pulmo-
nary hypertension?
Mr. Scarborough. That would make sense, given the
role of eNOS in producing NO, which then vasodilates the
vessels. There could be an adaptational up-regulation.
There may also be some circumstances surrounding
chronic hypoxia that would prevent the enzyme from
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doing its job, although the same could be said theoretically
about a decrease in eNOS enzyme itself causing pulmo-
nary hypertension. That, I believe, has been the contrast in
the past, trying to decide which one of those is the case. I
think enough studies have been conducted to suggest that
eNOS expression probably is increased. Studies in brown
humpback rats also lend support to that. The goal now is
to evaluate at the molecular level the reason that the
enzyme is not producing NO.
Dr. Hanley. Just one last comment: We are trying to get
around this cause-and-effect thing. If your house is not on
fire, there usually is not much water on it; if your house is
on fire, there is an increase in the amount of water on your
house, but that is not a paradox. In the same way, if a lung
is chronically hypoxic and vasoconstricted, the increase in
eNOS is just a reaction, even though eNOS is a vasodila-
tor. I do not find this paradox very difficult to understand
myself.
Mr. Scarborough. That is a good point. In fact, we
believe that we have shown that the pulmonary vascular
endothelium has retained its ability to produce NO de-
spite the hypoxic environment.
Dr. Fullerton. Does endothelin have an effect? Have
you measured any of that in the model?
Mr. Scarborough. We have not measured endothelin in
this model. That would be a good idea for future studies.
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